Skip to main content

Screening

Reviewed 05 Sept 2012

For the ‘average-risk’ population

  • Average risk individuals are those with no additional personal or familial risk factors for colorectal cancer, other than age greater than 50 years.
  • Several randomized studies have shown significant reduction in mortality from colorectal cancer in persons over 50 years of age who were screened by fecal occult blood testing (FOBT).
  • Other accepted modalities include fecal immunochemical testing (FIT), flexible sigmoidoscopy (with or without FOBT) and colonoscopy.
  • Modalities such as computed tomography colonography, and fecal DNA, are not consistently accepted as screening tools at this time.
  • Patient preference and resource availability should guide selection of a single screening method, but the best evidence recommends that FOBT of asymptomatic individuals between age 50 and 75 be performed every one or two years.
  • Positive tests on FOBT, FIT and flexible sigmoidoscopy should be followed by evaluation of the entire colon with colonoscopy.
  • If available, screening should be conducted within an organized program incorporating quality assurance and equitable access rather than opportunistic screening.
  • Recommendations for routine screening in British Columbia have been developed and approved by MSP (see BCGuidelines.ca - Gastrointestinal System).
  • Additional information regarding the provincial colorectal cancer screening initiative is available on the BC Cancer Colon Screening Program website.

Inflammatory Bowel Disease

  • Risk of colorectal cancer in IBD depends on IBD-related factors such as disease extent, disease duration, dysplasia, concomitant primary sclerosing cholangitis, and non-IBD factors including family history of colorectal cancer.
  • Specific recommendations regarding frequency and type of screening is generally as per the treating gastroenterologist.

Hereditary/Genetic Syndromes

  • Approximately 10% of patients with colorectal cancer display a hereditary pattern.
  • Persons with one or more first-degree relatives diagnosed with colon or rectal cancer should consider screening at age 40 with colonoscopy.
  • Hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome) accounts for 1-3% of all colorectal cancers, and displays an autosomal dominant pattern of inheritance. Due to germline mutations of the mismatch repair genes, the resulting microsatellite instability is clinically manifested by a lifetime risk of colorectal cancer between 40-90%, earlier presentation of colorectal cancer (compared to sporadic), and increased risk for extra-colonic malignancy. Individuals satisfying the Bethesda criteria (see BC Cancer Hereditary Cancer Program (HCP)) should be tested for HNPCC and if confirmed, be enrolled in a surveillance program of colonoscopy beginning at 20-25 years of age among mutation carriers, and then every 1-2 years. Extra-colonic cancer screening is also recommended.
  • Familial adenomatous polyposis (FAP, including Gardner Syndrome) is responsible for 1% of colorectal cancer presentations, and is secondary to mutations of the adenomatous polyposis coli (APC) gene. Inherited in an autosomal dominant pattern, individuals develop 100-1000 adenomatous colonic polyps by the second to third decade of life, with a 90% risk of progressing to colorectal cancer. Diagnosis is established by genetic testing. Individuals at risk (carriers or indeterminate relatives) are recommended to have yearly flexible sigmoidoscopy beginning at puberty. Once polyposis is identified, colectomy should be performed, as the risk then rises to 100%. If there is rectal sparing, a subtotal colectomy with ileorectal anastomosis can be performed. If not, a total proctocolectomy with ileal pouch-anal anastomosis or end ileostomy should be performed. Gastric and duodenal polyps and ampullary cancer are at increased risk of development, and should be screened for with esophagogastroduodenoscopy and biopsy.
  • Relatives of individuals with genetically confirmed mutations should also be tested.
  • Please refer to the BC Cancer Hereditary Cancer Program (HCP) for description and indications for referral to HCP regarding:
    • Hereditary Colorectal Cancer
    • Familial Adenomatous Polyposis and other polyposis syndromes


SOURCE: Screening ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2021 Provincial Health Services Authority